D.E. Shaw & Co
VRDN icon

D.E. Shaw & Co’s Viridian Therapeutics VRDN Stock Holding History

D.E. Shaw & Co’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.7M Buy
1,262,540
+261,823
+26% +$7.78M 0.01% 1019
2025
Q4 		$31.1M Buy
+1,000,717
New +$27.4M 0.02% 974
2025
Q2 		– Sell
-81,383
Closed -$1.1M – 4743
2025
Q1 		$1.1M Sell
81,383
-360,687
-82% -$6.14M ﹤0.01% 3029
2024
Q4 		$8.47M Buy
442,070
+304,003
+220% +$6.61M 0.01% 1608
2024
Q3 		$3.14M Buy
+138,067
New +$2.26M ﹤0.01% 2341
2023
Q1 		– Sell
-338,167
Closed -$9.88M – 4902
2022
Q4 		$9.88M Sell
338,167
-290,108
-46% -$6.68M 0.01% 1438
2022
Q3 		$12.9M Sell
628,275
-130,853
-17% -$2.35M 0.02% 1153
2022
Q2 		$8.78M Sell
759,128
-23,967
-3% -$322K 0.01% 1512
2022
Q1 		$14.5M Buy
783,095
+18,482
+2% +$355K 0.01% 1279
2021
Q4 		$15.1M Buy
764,613
+44,083
+6% +$821K 0.01% 1298
2021
Q3 		$11.9M Buy
720,530
+157
+0% +$2.3K 0.01% 1383
2021
Q2 		$13.2M Buy
720,373
+531,861
+282% +$9.1M 0.01% 1281
2021
Q1 		$3.15M Buy
+188,512
New +$3.53M ﹤0.01% 2200
2019
Q4 		– Sell
-1,127
Closed -$12K – 4196
2019
Q3 		$12K Sell
1,127
-1,769
-61% -$39.1K ﹤0.01% 3762
2019
Q2 		$89K Sell
2,896
-2,814
-49% -$113K ﹤0.01% 3556
2019
Q1 		$239K Buy
5,710
+1,770
+45% +$80.1K ﹤0.01% 3324
2018
Q4 		$179K Buy
+3,940
New +$228K ﹤0.01% 3566

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

D.E. Shaw & Co's VRDN Position: Q1 2026 in Review

D.E. Shaw & Co increased its Viridian Therapeutics (VRDN) stake by 26% in Q1 2026, buying an estimated $7.78M and bringing the position to 1,262,540 shares worth $24.7M. The position accounts for 0.01% of the portfolio, ranked #1019.

D.E. Shaw & Co first reported a position in VRDN in Q4 2018 and has held it in 17 quarters since. The position peaked at $31.1M in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • D.E. Shaw & Co held 1,262,540 shares of Viridian Therapeutics worth $24.7M as of Q1 2026.
  • D.E. Shaw & Co bought 261,823 Viridian Therapeutics shares in Q1 2026, an estimated $7.78M.
  • Viridian Therapeutics made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1019 holding.
  • D.E. Shaw & Co first reported a position in Viridian Therapeutics in Q4 2018 and has held it in 17 quarters since.
  • D.E. Shaw & Co's Viridian Therapeutics position peaked at $31.1M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.